Philippe Moreau

107.7k total citations · 12 hit papers
1.0k papers, 32.4k citations indexed

About

Philippe Moreau is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Philippe Moreau has authored 1.0k papers receiving a total of 32.4k indexed citations (citations by other indexed papers that have themselves been cited), including 757 papers in Hematology, 452 papers in Oncology and 449 papers in Molecular Biology. Recurrent topics in Philippe Moreau's work include Multiple Myeloma Research and Treatments (677 papers), Protein Degradation and Inhibitors (273 papers) and Peptidase Inhibition and Analysis (170 papers). Philippe Moreau is often cited by papers focused on Multiple Myeloma Research and Treatments (677 papers), Protein Degradation and Inhibitors (273 papers) and Peptidase Inhibition and Analysis (170 papers). Philippe Moreau collaborates with scholars based in France, United States and Spain. Philippe Moreau's co-authors include Jean‐Luc Harousseau, Thierry Façon, Hervé Avet‐Loiseau, Michel Attal, Jesús F. San Miguel, Régis Bataille, Cyrille Touzeau, Meletios Α. Dimopoulos, Paul G. Richardson and Xavier Leleu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Philippe Moreau

953 papers receiving 31.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

2005 992 citations Philippe Moreau et al. profile →
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011 661 citations Philippe Moreau, Xavier Leleu et al. profile →
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Jesús F. San Miguel et al. profile →
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017 392 citations Cyrille Hulin, Pellegrino Musto et al. Journal of Clinical Oncology profile →
Chemotherapy‐driven dysbiosis in the intestinal microbiome

2015 365 citations Thomas Gastinne, Philippe Moreau et al. profile →
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

2018 364 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

2020 256 citations Michèle Cavo, Kenshi Suzuki et al. profile →
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020 233 citations Michel Attal, Philippe Moreau et al. Journal of Clinical Oncology profile →
Extramedullary disease in multiple myeloma: a systematic literature review

2022 111 citations Joan Bladé, Philippe Moreau et al. profile →
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

2023 77 citations Noopur Raje, Sagar Lonial et al. profile →
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Philippe Moreau et al. profile →

Peers

Countries citing papers authored by Philippe Moreau

Since Specialization

Citations

This map shows the geographic impact of Philippe Moreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Moreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Moreau more than expected).

Fields of papers citing papers by Philippe Moreau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Moreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Moreau. The network helps show where Philippe Moreau may publish in the future.

Co-authorship network of co-authors of Philippe Moreau

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Moreau. A scholar is included among the top collaborators of Philippe Moreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Moreau. Philippe Moreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications 2024 ·Blood Advances ·Éric Letouzé, Philippe Moreau, Nikhil Munshi, Mehmet Samur, Stéphane Minvielle, Cyrille Touzeau	18
2	Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis 2023 ·Haematologica ·Thierry Façon, Philippe Moreau, Ross Baker, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M. Armstrong, Christina Tekle, (unknown), Marie‐Laure Risse, Thomas G. Martin	11
3	New Developments in Myeloma Treatment and Response Assessment 2023 ·Journal of Nuclear Medicine ·Françoise Kraeber‐Bodéré, Bastien Jamet, (unknown), Elena Zamagni, Philippe Moreau, Cristina Nanni	9
4	Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis 2021 ·Transplantation and Cellular Therapy ·Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michèle Cavo, Philippe Moreau, Meletios Α. Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie‐Laure Risse, Joseph Mıkhael	2
5	Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study 2021 ·Transplantation and Cellular Therapy ·Noopur Raje, David S. Siegel, Sundar Jagannath, Sagar Lonial, Nikhil C. Munshi, Philippe Moreau, Hartmut Goldschmidt, Michèle Cavo, Anna Truppel-Hartmann, Everton Rowe, Liping Huang, Amit Agarwal, Julie Wang, Timothy Campbell, Jesús F. San Miguel, Donna Reece	2
6	First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·Ravi Vij, Rajneesh Nath, Daniel Afar, María‐Victoria Mateos, Jesús G. Berdeja, Marc S. Raab, Andreas Guenther, Joaquín Martínez‐López, Andrzej Jakubowiak, Xavier Leleu, Katja Weisel, Shekman Wong, (unknown), James P. Sheridan, Anita Reddy, Bruno Paiva, Anil Singhal, Jesús F. San Miguel, Philippe Moreau	24
7	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study 2018 ·Clinical Cancer Research ·Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugène, Cyrille Touzeau, Michel Attal, Cyrille Hulin, Thierry Façon, Xavier Leleu, Aurore Perrot, Laurent Garderet, Margaret Macro, Denis Caillot, Philippe Moreau, Françoise Kraeber‐Bodéré, Caroline Bodet‐Milin	20
8	Prevalence of the reversed halo sign in neutropenic patients compared with non‐neutropenic patients: Data from a single‐centre study involving 27 patients with pulmonary mucormycosis (2003‐2016) 2017 ·Mycoses ·Jessie Bourcier, (unknown), Florent Morio, Thomas Gastinne, Patrice Chevallier, Fanny Rialland, Claire F. Garandeau, Isabelle Danner‐Boucher, Patrice Le Pape, Éric Frampas, Philippe Moreau, (unknown), Pierre Péterlin	26
9	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma 2016 ·Clinical Cancer Research ·Florence Magrangeas, Rowan Kuiper, Hervé Avet‐Loiseau, Wilfried Gouraud, Catherine Guérin‐Charbonnel, Ludovic Ferrer, Alexandre Aussem, Haytham Elghazel, (unknown), (unknown), Michel Attal, Nikhil C. Munshi, Pieter Sonneveld, Charles Dumontet, Philippe Moreau, Mark van Duin, L. Campion, Stéphane Minvielle	30
10	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 2013 ·Journal of Clinical Oncology ·Pieter Sonneveld, Hartmut Goldschmidt, Laura Rosiñol, Joan Bladé, Juan José Lahuerta, Michèle Cavo, Paola Tacchetti, Elena Zamagni, Michel Attal, Henk M. Lokhorst, Avinash Desai, Andrew Cakana, Kevin Liu, Helgi van de Velde, Dixie‐Lee Esseltine, Philippe Moreau	150
11	Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells 2012 ·Cancer Research ·Sylvanie Surget, David Chiron, Patricia Gomez‐Bougie, Géraldine Descamps, Emmanuelle Ménoret, Régis Bataille, Philippe Moreau, Steven Le Gouill, Martine Amiot, Catherine Pellat‐Deceunynck	58
12	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma 2012 ·Cancer Research ·Jill Corre, (unknown), Nicolas Espagnolle, Benjamin Hébraud, Hervé Avet‐Loiseau, Murielle Roussel, Anne Huynh, Mélanie Gadelorge, Pierre Cordelier, Bernard Klein, Philippe Moreau, Thierry Façon, Jean‐Jacques Fournié, Michel Attal, Philippe Bourin	76
13	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials 2011 ·Blood ·Peter Fayers, Antonio Palumbo, Cyrille Hulin, Anders Waage, Pierre W. Wijermans, Meral Beksaç, Sara Galimberti, Jean–Yves Mary, Peter Gimsing, Fabian Termorshuizen, Rauf Haznedar, Tommaso Caravita, Philippe Moreau, Ingemar Turesson, Pellegrino Musto, Lotfi Benboubker, M. Ronald Schaafsma, Pieter Sonneveld, Thierry Façon, (unknown)	179
14	ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2 high /Mcl-1 low Profile and Synergizes with Other Antineoplastic Agents 2011 ·Clinical Cancer Research ·Cyrille Touzeau, Christelle Dousset, (unknown), Patricia Gomez‐Bougie, Stéphanie Bonnaud, Philippe Moreau, Catherine Pellat‐Deceunynck, Martine Amiot, Steven Le Gouill	49
15	Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study 2010 ·Blood ·Philippe Moreau, Arnaud Jaccard, Lotfi Benboubker, Bruno Royer, Xavier Leleu, Frank Bridoux, Gilles Salles, Véronique Leblond, Murielle Roussel, May Alakl, Olivier Hermine, Lucie Planche, Jean‐Luc Harousseau, Jean‐Paul Fermand	96
16	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? 2010 ·Blood ·Hervé Avet‐Loiseau, Florent Malard, L. Campion, Florence Magrangeas, Catherine Sebban, Bruno Lioure, Olivier Decaux, Thierry Lamy, Laurence Legros, Jean‐Gabriel Fuzibet, Mauricette Michallet, Bernadette Corront, Pascal Lenain, Cyrille Hulin, Claire Mathiot, Michel Attal, Thierry Façon, Jean‐Luc Harousseau, Stéphane Minvielle, Philippe Moreau, (unknown)	92
17	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences 2010 ·Journal of Clinical Oncology ·Bart Barlogie, Michel Attal, John Crowley, Frits van Rhee, Jackie Szymonifka, Philippe Moreau, Brian G.M. Durie, Jean‐Luc Harousseau	103
18	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) 2010 ·Journal of Clinical Oncology ·Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Philippe Moreau, Catherine Guérin‐Charbonnel, Denis Caillot, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Claire Mathiot, Brigitte Kolb, Margaret Macro, L. Campion, Marc Wetterwald, Anne‐Marie Stoppa, Cyrille Hulin, Thierry Façon, Michel Attal, Stéphane Minvielle, Jean‐Luc Harousseau	298
19	Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial 2009 ·Journal of Clinical Oncology ·Cyrille Hulin, Thierry Façon, Philippe Rodon, Brigitte Pegourié, Lotfi Benboubker, Chantal Doyen, Mamoun Dib, Gaëlle Guillerm, Bruno César Corrêa Salles, Jean‐Paul Eschard, Pascal Lenain, Philippe Casassus, I Azaïs, Olivier Decaux, Laurent Garderet, Claire Mathiot, Jean Fontan, Ingrid Lafon, J.-M. Virion, Philippe Moreau	266
20	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome 2008 ·Journal of Clinical Oncology ·Olivier Decaux, Laurence Lodé, Florence Magrangeas, Catherine Guérin‐Charbonnel, Wilfried Gouraud, Pascal Jézéquel, Michel Attal, Jean‐Luc Harousseau, Philippe Moreau, Régis Bataille, L. Campion, Hervé Avet‐Loiseau, Stéphane Minvielle	269

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact